LXRX - LEXICON PHARMACEUTICALS, INC.
IEX Last Trade
0.7443
-0.045 -5.979%
Share volume: 0
Last Updated: Fri 27 Dec 2024 03:30:05 PM CET
Research and Development in Biotechnology (except Nanobiotechnology):
-1.15%
PREVIOUS CLOSE
CHG
CHG%
$0.79
-0.04
-5.64%
View ratios
Fiscal Date | 2022-09-30 | 2022-12-31 | 2023-03-31 | 2023-06-30 | 2023-09-30 | 2023-12-31 | 2024-03-31 | 2024-06-30 | |
---|---|---|---|---|---|---|---|---|---|
Fiscal Quarter | Q3 2022 | Q4 2022 | Q1 2023 | Q2 2023 | Q3 2023 | Q4 2023 | Q1 2024 | Q2 2024 | |
Report Date | 2022-11-09 | 2023-03-03 | 2023-05-04 | 2023-08-04 | 2023-11-08 | 2024-03-25 | 2024-05-02 | 2024-08-02 | |
Total revenue | 39.000 K | 28.000 K | 24.000 K | 317.000 K | 162.000 K | 701.000 K | 1.130 M | 1.647 M | |
Cost of revenue | 0.000 | 0.000 | 0.000 | 8.000 K | 7.000 K | 70.000 K | 31.000 K | 166.000 K | |
Gross profit | 39.000 K | 28.000 K | 24.000 K | 309.000 K | 155.000 K | 631.000 K | 1.099 M | 1.481 M | |
-28.21% | -14.29% | 1,187.50% | -49.84% | 307.10% | 74.17% | 34.76% | |||
Operating expenses | 23.134 M | 30.306 M | 31.166 M | 44.549 M | 49.786 M | 47.368 M | 46.432 M | 56.835 M | |
Selling general and admin | 12.577 M | 16.329 M | 19.140 M | 30.008 M | 32.228 M | 32.606 M | 32.060 M | 39.192 M | |
Research and development | 10.557 M | 13.977 M | 12.026 M | 14.541 M | 17.558 M | 14.762 M | 14.372 M | 17.643 M | |
Total expenses | 23.134 M | 30.306 M | 31.166 M | 44.557 M | 49.793 M | 47.438 M | 46.463 M | 57.001 M | |
31.00% | 2.84% | 42.97% | 11.75% | -4.73% | -2.06% | 22.68% | |||
Operating income | -23.095 M | -30.278 M | -31.142 M | -44.240 M | -49.631 M | -46.737 M | -45.333 M | -55.354 M | |
Ebit | -23.095 M | -30.278 M | -31.142 M | -44.240 M | -49.631 M | -46.737 M | -45.333 M | -55.354 M | |
Pretax income | -23.387 M | -30.494 M | -31.934 M | -44.904 M | -50.525 M | -49.756 M | -48.397 M | -53.429 M | |
30.39% | 4.72% | 40.62% | 12.52% | -1.52% | -2.73% | 10.40% | |||
Income tax | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
Net income basic | -23.387 M | -30.494 M | -31.934 M | -44.904 M | -50.525 M | -49.756 M | -48.397 M | -53.429 M | |
-30.39% | -4.72% | -40.62% | -12.52% | 1.52% | 2.73% | -10.40% | |||
Net income | -23.387 M | -30.494 M | -31.934 M | -44.904 M | -50.525 M | -49.756 M | -48.397 M | -53.429 M | |
-30.39% | -4.72% | -40.62% | -12.52% | 1.52% | 2.73% | -10.40% |